Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vanda Pharmaceuticals (NQ: VNDA )

4.555 +0.075 (+1.67%)
Streaming Delayed Price Updated: 11:22 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanda Pharmaceuticals

< Previous 1 2 3 4 Next >
Vanda Pharma: Q3 Earnings Insights
Via Benzinga
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
Earnings Outlook For Vanda Pharma
Via Benzinga
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday
The pharmaceutical company's stock hit another 52-week low. 
Via The Motley Fool
Earnings Preview: Vanda Pharmaceuticals
Via Benzinga
Vanda Pharma's Antipsychotic Shows Improved Severity In Bipolar Disorder
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday morning, 164 companies achieved new lows for the year. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Looking Into Vanda Pharmaceuticals's Return On Capital Employed
  
Via Benzinga
Recap: Vanda Pharma Q2 Earnings
Vanda Pharma (NASDAQ:VNDA) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 59 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test
Via Benzinga
Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 135 companies reached new 52-week lows. 
Via Benzinga
Why Vanda Pharmaceuticals Stock Crawled Higher Today
A solid earnings beat drove the company's share price upward. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 498 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday's trading, 293 companies set new 52-week lows. 
Via Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 115 stocks hit new 52-week lows. 
Via Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For November 2, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. 
Via Benzinga
Earnings Outlook For Vanda Pharmaceuticals
Vanda Pharmaceuticals (NASDAQ:VNDA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vanda... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.